These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 10926212)
1. Catalytic antibodies as magic bullets. Rader C; List B Chemistry; 2000 Jun; 6(12):2091-5. PubMed ID: 10926212 [TBL] [Abstract][Full Text] [Related]
2. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Bodey B; Bodey B; Siegel SE; Kaiser HE Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379 [TBL] [Abstract][Full Text] [Related]
4. [Progress in monoclonal antibody-based immunotherapy for cancer treatment]. Guo Y Sheng Wu Gong Cheng Xue Bao; 2015 Jun; 31(6):857-70. PubMed ID: 26672362 [TBL] [Abstract][Full Text] [Related]
5. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
6. Catalytic activity of certain antibodies as a potential tool for drug synthesis and for directed prodrug therapies. Wójcik T; Kieć-Kononowicz K Curr Med Chem; 2008; 15(16):1606-15. PubMed ID: 18673227 [TBL] [Abstract][Full Text] [Related]
7. Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304 [TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory properties of anticancer monoclonal antibodies: is the 'magic bullet' still a reliable paradigm? Correale P; Cusi MG; Tagliaferri P Immunotherapy; 2011 Jan; 3(1):1-4. PubMed ID: 21174549 [No Abstract] [Full Text] [Related]
9. A magic bullet for cancer--how near and how far? Schnipper LE; Strom TB N Engl J Med; 2001 Jul; 345(4):283-4. PubMed ID: 11474668 [No Abstract] [Full Text] [Related]
10. Paul Ehrlich's magic bullet concept: 100 years of progress. Strebhardt K; Ullrich A Nat Rev Cancer; 2008 Jun; 8(6):473-80. PubMed ID: 18469827 [TBL] [Abstract][Full Text] [Related]
11. From "magic bullets" to specific cancer immunotherapy. Riether C; Schürch C; Ochsenbein AF Swiss Med Wkly; 2013; 143():w13734. PubMed ID: 23348718 [TBL] [Abstract][Full Text] [Related]
12. [Catalytic autoantibodies and their future in practical medicine]. Suchkov SV; Gabibov AG; Alekberova ZS; Paleev FN; Gnuchev NV Ter Arkh; 2002; 74(10):40-5. PubMed ID: 12469630 [No Abstract] [Full Text] [Related]
13. The therapeutic potential for catalytic antibodies: from a concept to a promise. Jones LH; Wentworth P Mini Rev Med Chem; 2001 Jul; 1(2):125-32. PubMed ID: 12369978 [TBL] [Abstract][Full Text] [Related]
14. Catalytic antibodies and their applications. Hanson CV; Nishiyama Y; Paul S Curr Opin Biotechnol; 2005 Dec; 16(6):631-6. PubMed ID: 16243512 [TBL] [Abstract][Full Text] [Related]
15. Labeled antigens and antibodies: the evolution of magic markers and magic bullets. Silverstein AM Nat Immunol; 2004 Dec; 5(12):1211-7. PubMed ID: 15549122 [TBL] [Abstract][Full Text] [Related]
16. Advances in Cancer Therapy: Immunotherapies. Marmé D Oncol Res Treat; 2016; 39(6):324-5. PubMed ID: 27260772 [No Abstract] [Full Text] [Related]
17. Catalytic antibodies: the concept and the promise. Lerner RA Hosp Pract (Off Ed); 1993 Jul; 28(7):53-9. PubMed ID: 8325916 [TBL] [Abstract][Full Text] [Related]
18. Oligo-branched peptides for tumor targeting: from magic bullets to magic forks. Falciani C; Pini A; Bracci L Expert Opin Biol Ther; 2009 Feb; 9(2):171-8. PubMed ID: 19236247 [TBL] [Abstract][Full Text] [Related]